gms | German Medical Science

71. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
9. Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

21.06. - 24.06.2020

The effect of advanced glycation endproducts on meningioma cells

Der Einfluss von Advanced Glycation Endproducts auf Meningeomzellen

Meeting Abstract

Suche in Medline nach

  • presenting/speaker Maximilian Scheer - Universitätsklinikum Halle-Wittenberg, Neurochirurgie, Halle/Saale, Deutschland
  • Christian Strauss - Universitätsklinikum Halle-Wittenberg, Neurochirurgie, Halle/Saale, Deutschland
  • Philipp Selke - Universitätsklinikum Halle-Wittenberg, Neurochirurgie, Halle/Saale, Deutschland
  • Rüdiger Horstkorte - Universitätsklinikum Halle-Wittenberg, Neurochirurgie, Halle/Saale, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 71. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), 9. Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie. sine loco [digital], 21.-24.06.2020. Düsseldorf: German Medical Science GMS Publishing House; 2020. DocV038

doi: 10.3205/20dgnc042, urn:nbn:de:0183-20dgnc0423

Veröffentlicht: 26. Juni 2020

© 2020 Scheer et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objective: Meningiomas are the most common tumor in the brain. Like most other tumors, also meningioma prefer anaerobic glycolysis for energy production (Warburg effect). This results in an increased formation of the metabolite methylglyoxal (MGO), which is known to react with aminogroups of proteins thereby forming advanced glycation endproducts (AGEs).In this study, we investigated the influence of AGEs on growth and adhesion. We used two meningioma cell lines, representing the WHO grade I (BEN-MEN-1) or the WHO grade III (IOMM-Lee). We cultured both cell line in the absence or presence of MGO.

Methods: Figure 1 [Fig. 1]: Meningioma cell lines (BEN-MEN-1 [A,C] and IOMM-Lee [B,D]) were incubated for 24 h with different concentrations of MGO in low serum containing medium (1 % FCS). The images in Figure 1 A and B [Fig. 1] were taken with brightfield microscopy. Scale bar correspond to 100 µm. Proteins were isolated and glycation were detected by western blot using a monoclonal CML (Carboxymethyl-Lysin)-26 antibody. Representative blots from at least 3 independent experiments are shown (Figure 1 C and D [Fig. 1]).

Figure 2 [Fig. 2]: The adhesion of both meningioma cell lines was measured by Real Time Cell Analyzer (RTCA). The E-Plates were coated with 10 µg/ml of fibronectin (FN; A) or collagen IV (ColIV; B) for 1 h. The matrix was treated for 24 h with 0.3 mM MGO. After washing with 1x PBS, plates were blocked with 0.5 % BSA for 1 h. Then, cells were seeded in a concentration of 50000 cells/ml in a total volume of 100 µl of low serum medium (1% FCS) and treated with 0.3 mM MGO. Data in Figure 2 A and B [Fig. 2] represents average mean ±SD of 4 independent experiments.

Results: Treatment of cells with MGO has no effect on cell viability in low concentrations in both cell lines. However, at higher concentrations, MGO is cytotoxic in both cell lines. Furthermore, the Western blot analysis reveals a concentration-dependent formation of AGEs, which could be detected with the antibody CML-26. In the analysis of adhesion, differences were found on the different media, depending on the cell line. A change of adhesion by glycation with a low concentration of MGO could not be observed.

Conclusion: These first results indicate that MGO has an influence on the growth, but there is no effect of 0.3 mM MGO on the adhesion of both meningioma cell lines. The WHO Grade I cells have a stronger adhesion to the matrix compared with the WHO Grade III cells. Additionally, the cells have a different adhesion to fibronectin compared with collagen IV.